HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E4849 Terbutaline Terbutaline(Brican, Brethine), an active metabolite of bambuterol is an orally active agonist of β2-adrenergic receptor, that increases MKP-1 expression. Terbutaline is used in the treatment of obstructive lung diseases as a bronchodilator remedy. It also exhibits anti-inflammatory effects. Sep 23 2024
E4913 Calcifediol monohydrate Calcifediol monohydrate(25-hydroxy Vitamin D3 monohydrate), is an effective vitamin D receptor (VDR) ligand and VD supplement. It acts as an inhibitor of vitamin D receptor (VDR) Calcifediol is a prohormone of the vitamin D endocrine system (VDES) and is hydroxylated in the liver to produce the active form, calcitriol. Calcifediol can rapidly increase serum VD levels. Sep 23 2024
E4925 Amsacrine Amsacrine(m-AMSA; acridinyl anisidide) is an inhibitor of topoisomerase II. Amsacrine acts as an antineoplastic agent which intercalates into the DNA of tumor cells, it is also used in the treatment of acute myelogenous leukemia. Sep 23 2024
E4874 Lumateperone Tosylate Lumateperone tosylate(ITI-007) is an antagonist of 5-HT2A receptor. It also acts as a partial agonist of presynaptic D2 receptors, as an antagonist of postsynaptic D2 receptors, and as a modulator of dopamine D1 receptor. Lumateperone tosylate demonstrates anticancer activity. Sep 23 2024
E4957 Mozavaptan (hydrochloride) Mozavaptan hydrochloride(OPC 31260 HCl), a benzazepine derivative is a potent, selective, competitive, and orally active antagonist of vasopressin V2 receptor with an IC50 value of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V2 receptor over V1 receptor. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment. Sep 23 2024
E4951 Eprosartan Eprosartan(Teveten, SK-108566) is a selective, competitive, nonpeptide and orally active antagonist of angiotensin II receptor. Eprosartan binds angiotensin II receptors with IC50 values of 9.2 nM and 3.9 nM in rat and human adrenal cortical membranes, respectively. Sep 23 2024
E1910 TASIN-30 TASIN-30 is a selective inhibitor of Emopamil binding protein (EBP) with EC50 values of 0.097 μM for EBP competition, respectively. TASIN-30 displays selectivity for EBP over DHCR24. Sep 23 2024
E4939 Sulfisoxazole acetyl Sulfisoxazole acetyl(N1-Acetylsulfisoxazole, Acetyl sulfafurazole), a sulfisoxazole derivative, is an orally active inhibitor of dihydropteroate synthase. Sulfisoxazole acetyl can be biotransformed primarily to sulfisoxazole, and partly to N(4)-acetyl sulfisoxazole (N4AS). Sulfisoxazole acetyl exhibits antibacterial action. Sep 23 2024
E4648 Pico145 Pico145(HC-608) is a selective inhibitor of TRPC1/4/5 channels. It inhibits (−)-englerin A-activated TRPC4/TRPC5 channels, with IC50 values of 0.349 and 1.3 nM, respectively. It exhibits no effect on TRPC3, TRPC6, TRPV1, TRPV4, TRPA1, TRPM2, TRPM8. Sep 23 2024
E1637 ALKBH5 inhibitor 1 (compound 3) ALKBH5 inhibitor 1 (compound 3) is an inhibitor of the RNA m6A Demethylase ALKBH5, with an IC50 value of 0.84 μM. It also exhibits potent antiproliferative activity. Sep 19 2024
E1785 PF-06952229 PF-06952229(UNII-1KKS7U3X86) is a selective, orally available inhibitor of the serine/threonine kinase TGF-β receptor 1 (TGF-β-R1). It inhibits pSMAD2 in both tumor and immune cells, reducing TGF-β signalling and reversing EMT in vitro. It modulates the tumor immune microenvironment and shows antitumor activity in mouse models. Sep 19 2024
E4700 ML-099 ML099(CID-888706) is a pan-activator of Ras-related GTPases. It enhances GTPase activity by increasing its affinity for guanine nucleotides through binding to an allosteric site between switch regions I and II. Sep 19 2024
E1972 AZD8421 AZD8421 is a potent and highly selective inhibitor of Cyclin-dependent Kinase 2 (CDK2), with an IC50 against CDK2 of 9nM with selectivity over CDK1, CDK4 and CDK6. It also exhibits an anti-proliferative effect, effectively inhibits Rb phosphorylation, and shows strong activity both as a monotherapy and in combination with CDK4/6 inhibitors in breast and ovarian cancer models. Sep 18 2024
E1834 iMDK iMDK is a potent inhibitor of PI3K. It also inhibits the growth factor MDK (also known as midkine or MK). iMDK use along with a MEK inhibitor suppresses tumor growth of non-small cell lung cancer (NSCLC), including KRAS-mutant NSCLC and squamous NSCLC. Sep 18 2024
E4930 Asenapine Asenapine(Org 5222, HSDB8061) is a multi-target receptor antagonist. It acts as an antagonist of serotonin receptors with pKi values of 8.4-10.5, adrenoceptors with pKi values of 8.9-9.5, dopamine receptors with pKi values of 8.9-9.4 and histamine receptors with pKi values of 8.2-9.0. Sep 18 2024
E4949 Eslicarbazepine Eslicarbazepine (BIA 2-194), an active metabolite of the prodrug eslicarbazepine acetate is an inhibitor of voltage-gated sodium channel (Nav). It acts by enhancing the slow activation of voltage-gated sodium channels, reducing their availability. Sep 18 2024
E4918 BecloMethasone Beclomethasone(Beclometasone) is a prototype agonist of glucocorticoid receptor. Beclomethasone and its derivatives display have higher binding affinity to glucocorticoid receptors in rat liver, thymus, and hypophysis. Sep 18 2024
E4964 ATP disodium trihydrate ATP disodium trihydrate, is the primary energy currency of the cell, essential for intracellular energy metabolism. It regulates extracellular biological processes, including cardiac function, neurotransmission, muscle contraction, vasodilation, bone and liver glycogen metabolism, and inflammation. It also plays a crucial role in initiating immune responses during infections. Sep 13 2024
E4661 dWIZ-2 dWIZ-2, is a molecular glue degrader of the WIZtranscription factor degrading WIZ with a DC50 of 32 nM. It also robustly induces fetal hemoglobin (HbF) in erythroblasts with an EC50 of 202 nM. Sep 13 2024
E4914 Cabozantinib hydrochloride Cabozantinib hydrochloride(XL184, BMS-907351 hydrochloride) is a potent small-molecule kinase inhibitor of c-MET and VEGFR2 with an IC50 of 1.3 nM, 0.035 nM respectively. It also inhibits RET, KIT, AXL, Tie2 and FLT3 with an IC50's of 5.2 nM, 4.6 nM, 7 nM, 14.3 nM, 11.3nM respectively. It can be promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling. Sep 13 2024